<?xml version='1.0' encoding='UTF-8'?>
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="publisher-id">nss</journal-id>
      <journal-title-group>
        <journal-title>Nature and Science of Sleep</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1179-1608</issn>
      <publisher>
        <publisher-name>Dove</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">36394065</article-id>
      <article-id pub-id-type="pmc">9656355</article-id>
      <article-id pub-id-type="publisher-id">385755</article-id>
      <article-id pub-id-type="doi">10.2147/NSS.S385755</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>MiR-142-3p as an Indicator of OSA Severity Predicts Prognosis in Lung Adenocarcinoma with OSA</article-title>
        <alt-title alt-title-type="running-authors">Yang et al</alt-title>
        <alt-title alt-title-type="running-title">Yang et al</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5469-6363</contrib-id>
          <name>
            <surname>Yang</surname>
            <given-names>Ting</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>He</surname>
            <given-names>Fang</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Mingxiang</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ai</surname>
            <given-names>Li</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>He</surname>
            <given-names>Meng</given-names>
          </name>
          <xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Xin</given-names>
          </name>
          <xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0829-6729</contrib-id>
          <name>
            <surname>Li</surname>
            <given-names>Yongxia</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
          <xref rid="an0001" ref-type="corresp"/>
        </contrib>
        <aff id="aff0001"><label>1</label><institution>Department of Respiratory, The Second Affiliated Hospital of Kunming Medical University</institution>, <addr-line>Yunnan</addr-line>, <addr-line>650000</addr-line>, <country>People’s Republic of China</country></aff>
        <aff id="aff0002"><label>2</label><institution>Department of Cardiothoracic Surgery, Children’s Hospital affiliated to Kunming Medical University</institution>, <addr-line>Yunnan</addr-line>, <addr-line>650000</addr-line>, <country>People’s Republic of China</country></aff>
        <aff id="aff0003"><label>3</label><institution>Department of Thoracic Surgery, The Second Affiliated Hospital of Kunming Medical University</institution>, <addr-line>Yunnan</addr-line>, <addr-line>650000</addr-line>, <country>People’s Republic of China</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="an0001">Correspondence: Yongxia Li, <institution>Department of Respiratory, The Second Affiliated Hospital of Kunming Medical University</institution>, <addr-line>Yunnan</addr-line>, <addr-line>650000</addr-line>, <country>People’s Republic of China</country>, Email liyongxia@kmmu.edu.cn</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>09</day>
        <month>11</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2022</year>
      </pub-date>
      <volume>14</volume>
      <fpage>2047</fpage>
      <lpage>2054</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>8</month>
          <year>2022</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2022 Yang et al.</copyright-statement>
        <copyright-year>2022</copyright-year>
        <copyright-holder>Yang et al.</copyright-holder>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref>
          <license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <sec id="s2001">
          <title>Purpose</title>
          <p><citation_analysis attribute="neither">The aim was to explore the correlation between Obstructive sleep apnea (OSA) and Lung adenocarcinoma malignant prognosis and evaluate the miR-142-3p was used as an OSA severity indicator to predict the prognosis of Lung adenocarcinoma patients.</citation_analysis></p>
        </sec>
        <sec id="s2002">
          <title>Methods</title>
          <p><citation_analysis attribute="neither">This study comprised of 21 diagnosed lung adenocarcinoma patients with or without OSA. The sleep-related variables and tumor pathology were recorded. Hypoxia-inducible factor-1α (HIF1α) and ki67 expression were analyzed by immunohistochemistry in tumor samples. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to assess the level of miR-142-3p.</citation_analysis></p>
        </sec>
        <sec id="s2003">
          <title>Results</title>
          <p><citation_analysis attribute="neither">Lung adenocarcinoma with OSA showed higher apnea-hypopnea index (AHI), oxygen desaturation index (ODI), and the lower lowest pulse oxygen saturation (LS</citation_analysis><citation_analysis attribute="positive"><sub>P</sub></citation_analysis><citation_analysis attribute="neither">O</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">) compared to Lung adenocarcinoma without OSA (P&lt;0.05), and patients with severer OSA have an advanced TNM stage (P=0.004) and metastasis rate (p=0.032). In addition, OSA may down-regulate the miR-142-3p expression in patients with Lung adenocarcinoma, and the patients with low miR-142-3p expression exhibited severe OSA. MiR-142-3p levels significantly decreased in the advanced TNM stage (p=0.015), and the expression of miR-142-3p was negatively associated with AHI (r= −0.505, p=0.020), ODI (r= −0.513, p=0.017).</citation_analysis></p>
        </sec>
        <sec id="s2004">
          <title>Conclusion</title>
          <p><citation_analysis attribute="neither">OSA severity may increase Lung adenocarcinoma malignant prognosis. OSA may down-regulate the expression of miR-42-3p. The expression of miR-142-3p was inversely correlated with AHI and ODI as a surrogate of OSA severity. Additionally, the low miR-142-3p expression level was significantly associated with advanced TNM stage in Lung adenocarcinoma patients.</citation_analysis></p>
        </sec>
      </abstract>
      <kwd-group kwd-group-type="author">
        <title>Keywords</title>
        <kwd>obstructive sleep apnea</kwd>
        <kwd>lung adenocarcinoma</kwd>
        <kwd>miR-142-3p</kwd>
        <kwd>HIF1α</kwd>
        <kwd>prognosis</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
<institution-wrap><institution>The Yunnan Science and Technology Planning Project</institution></institution-wrap>
</funding-source>
        </award-group>
        <funding-statement>This work was supported by The Yunnan Science and Technology Planning Project (201901B070066).</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="3"/>
        <table-count count="3"/>
        <ref-count count="35"/>
        <page-count count="8"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s0001">
      <title>Introduction</title>
      <p><citation_analysis attribute="positive">OSA is characterized by the collapse of the upper airway during sleep that results in recurrent oxyhemoglobin desaturation, and systemic inflammation leads to chronic intermittent hypoxia (IH), which can result in a complex series of pathophysiological changes,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="negative"> such as the increased risk for hypertension,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0002" ref-type="bibr">2</xref></citation_analysis><citation_analysis attribute="neither"> coronary heart disease,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0003" ref-type="bibr">3</xref></citation_analysis><citation_analysis attribute="neither"> stroke,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0004" ref-type="bibr">4</xref></citation_analysis><citation_analysis attribute="neither"> as well as cognitive impairment</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0005" ref-type="bibr">5</xref></citation_analysis><citation_analysis attribute="neither"> and even increased cancer incidence and mortality,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither"> especially in lung cancer</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0008" ref-type="bibr">8</xref></citation_analysis><citation_analysis attribute="neither"> and breast cancer.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0010" ref-type="bibr">10</xref></citation_analysis><citation_analysis attribute="neither"> As a marker of OSA, IH could be a vital factor in driving tumorigenesis and death.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> Some clinical sleep parameters are linked with the mortality of lung cancer patients with OSA. Previous studies have investigated cancer-related mortality in patients with OSA, and there was a dose-response relationship between OSA severity as measured by AHI and percentage of time spent with oxygen saturation below 90%(CT90) and cancer mortality.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0011" ref-type="bibr">11</xref></citation_analysis><citation_analysis attribute="negative"> Severe OSA is associated with an increased risk of cancer mortality in III–IV stage lung cancer patients, and AHI was positively related to hypoxia-inducible factor 1(HIF1α).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">IH is a hallmark manifestation of OSA that could causally modify cancer-related biological processes to promote cancer malignant progression, mediated mainly by the activated HIFs.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0012" ref-type="bibr">12</xref></citation_analysis><citation_analysis attribute="neither"> The vital role of HIF1a in tumor malignant progression and chemoresistance is now well established.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0013" ref-type="bibr">13</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0014" ref-type="bibr">14</xref></citation_analysis><citation_analysis attribute="positive"> Studies have demonstrated that hypoxia-repressed miR-142-3p by targets HIF1α, which provides therapeutic possibilities.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0015" ref-type="bibr">15</xref></citation_analysis><citation_analysis attribute="positive"> Accumulating evidence also has shown that miR-142-3p is downregulated in lung cancer.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0016" ref-type="bibr">16</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0017" ref-type="bibr">17</xref></citation_analysis><citation_analysis attribute="neither"> Therefore, we suspect that miR-142-3p plays a critical role in OSA-related IH-induced lung cancer progression.</citation_analysis></p>
      <p><citation_analysis attribute="positive">Most human studies to date have not yet explored the outcome of OSA in specific Lung adenocarcinoma sites. We analyzed the sleep parameters and characteristics of Lung adenocarcinoma patients with or without OSA to further evaluate the correlation between OSA and malignant tumor prognosis. Due to the biomarkers of OSA-related intermittent hypoxia not being fully evaluated, we assessed the correlation between the severity of OSA and the expression of miR-142-3p in Lung adenocarcinoma patients. In addition, we also analyzed the link between the miR-142-3p expression with cancer prognosis.</citation_analysis></p>
    </sec>
    <sec id="s0002">
      <title>Materials and Methods</title>
      <sec id="s0002-s2001">
        <title>Study Population</title>
        <p><citation_analysis attribute="positive">Tumor and adjacent normal tissues from Lung adenocarcinoma patients who underwent surgery from January 2021 to September 2021 were collected from The Second Affiliated Hospital of Kunming Medical University. Inclusion criteria were as follows: (1) molecular biology and pathology certified the diagnosis of Lung adenocarcinoma. The tumor stage was evaluated according to the guidelines of the eighth edition American Joint Committee on Cancer (AJCC).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0018" ref-type="bibr">18</xref></citation_analysis><citation_analysis attribute="neither"> (2) Clinicopathological characteristics were collected after a median follow-up of nine months, the follow-up deadline was September 20, 2022. Due to the short-term follow-up, endpoint events were defined as recurrence, metastasis, or death during the follow-up period. (3) Patients were diagnosed with OSA by pre-or postoperative polysomnogram (PSG). With AHI ≥5 as a screening criterion for OSA, patients were divided into mild (5≤AHI&lt;15), moderate (15≤AHI&lt;30), and severe OSA (AHI≥30) according to the standard guideline.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0019" ref-type="bibr">19</xref></citation_analysis><citation_analysis attribute="neither"> Sleep parameters including the AHI, ODI, LS</citation_analysis><citation_analysis attribute="positive"><sub>P</sub></citation_analysis><citation_analysis attribute="neither">O</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="positive">, and CT90 were recorded. The study has been submitted for approval by the Ethics Committee of The Second Affiliated Hospital of Kunming Medical University (PJ-2021-65) and conducted in accordance with the Declaration of Helsinki.</citation_analysis></p>
      </sec>
      <sec id="s0002-s2002">
        <title>Immunohistochemistry Staining</title>
        <p><citation_analysis attribute="positive">Lung adenocarcinoma tissues were dehydrated, embedded, sectioned, and baked, and slides were then counterstained with antigen retrieval; the sections were then blocked with 3% hydrogen peroxide and 5% goat serum (#SL038, Solarbio, China). Anti-HIF-1α antibody (#36169, 1:500, CST, USA) and anti-Ki67 antibody (#ab92742, 1:600, Abcam, UK) were incubated overnight at 4℃. Subsequently, the goat anti-rabbit antibody (#S0001, 1:5000, Affinity, USA) was incubated for 1 h at 37℃, followed by visualization with 3,3-diaminobenzidine. The stained slides were then examined and photographed using a microscope (BX43F, Olympus, Japan). The immunoreactivity of HIF1α and ki67 was categorized from negative (no staining), + (weak), ++ (moderate) and +++ (strong), and the percentage of staining was categorized as negative (≤ 5%), + (6–25%), ++ (26–50%), +++ (51–75%) and +++ (&gt; 75%). The final score was determined by the intensity and percentage score, and the scoring was calculated by Image-Pro Plus 7.</citation_analysis></p>
      </sec>
      <sec id="s0002-s2003">
        <title>Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)</title>
        <p><citation_analysis attribute="positive">MiRNA was isolated from tissues by RNAiso for small RNA (#9753A, Takara, Japan). The Mir-X miRNA First-Strand Synthesis Kit (#638315, Takara, Japan) was used for reverse transcription of miR-142-3p. According to the instructions for FastStart™ Universal SYBR® Green (#04913914001, Roche, Germany), amplification and quantification were performed on an ABI 7300/7500 system (Applied Biosystems). U6 was normalized to the reference genes for miR-142-3p. Data analysis was assessed to the 2</citation_analysis><citation_analysis attribute="positive"><sup>−ΔΔCt</sup></citation_analysis><citation_analysis attribute="neither"> method. Primers are detailed in </citation_analysis><citation_analysis attribute="positive"><xref rid="t0001" ref-type="table">Table 1</xref></citation_analysis><citation_analysis attribute="neither">.</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0001"><label>Table 1</label><caption><p><citation_analysis attribute="neither">Primers Used for qRT-PCR</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Gene</th><th rowspan="1" colspan="1">Primer Sequence</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">U6</td><td rowspan="1" colspan="1">Forward: 5’- CTCGCTTCGGCAGCACA - 3’</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Reverse: 5’- AACGCTTCACGAATTTGCGT - 3’</td></tr><tr><td rowspan="1" colspan="1">MiR-142-3p</td><td rowspan="1" colspan="1">5’- GCGCGTGTAGTGTTTCCTACTTTATGG - 3’</td></tr></tbody></table></table-wrap></citation_analysis></p>
      </sec>
      <sec id="s0002-s2004">
        <title>Statistical Analysis</title>
        <p><citation_analysis attribute="positive">Statistical calculations were performed using SPSS 23.0 software and GraphPad Prism 9.0. Between the two groups, the Mann–Whitney U (non-normal distribution) or Student’s </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">t</italic></citation_analysis><citation_analysis attribute="positive">-test (normal distribution) was used for comparing continuous data, the categorical data were compared using the chi-square test or Fisher exact test. The differences among multiple groups were identified with the One-way Analysis of Variance (ANOVA). The correlation analysis of parameters was performed using the Pearson test. P values &lt; 0.05 were considered significant.</citation_analysis></p>
      </sec>
    </sec>
    <sec id="s0003">
      <title>Results</title>
      <sec id="s0003-s2001">
        <title>Sleep Parameters and Clinical Characteristics of Lung Adenocarcinoma Patient</title>
        <p><citation_analysis attribute="positive">A total of 21 Lung adenocarcinoma patients were included in the study, and the baseline characteristics of patients were classified into three groups according to OSA severity as measured by AHI, shown in </citation_analysis><citation_analysis attribute="positive"><xref rid="t0002" ref-type="table">Table 2</xref></citation_analysis><citation_analysis attribute="positive">. Due to the small number of participants with moderate and severe OSA, moderate-to-severe OSA patients were established as a group. The result showed that female Lung adenocarcinoma patients have a lower prevalence of OSA. The age, body mass index (BMI), and CT90 did not significantly differ among the three groups (P&gt;0.05). There were significant differences in three groups regarding AHI (p= 0.000), ODI (p= 0.000), and LS</citation_analysis><citation_analysis attribute="positive"><sub>P</sub></citation_analysis><citation_analysis attribute="neither">O</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither"> (p= 0.042). As expected, lung adenocarcinoma patient with severe OSA have a higher TNM stage (P=0.004) and metastasis rate (p=0.032). MiR-142-3p levels were lower in Group Lung adenocarcinoma with OSA than that in Lung adenocarcinoma, and the moderate to severe OSA (AHI≥15) group was lower than the mild OSA (5≤AHI&lt;15) (</citation_analysis><citation_analysis attribute="positive"><xref rid="t0002" ref-type="table">Table 2</xref></citation_analysis><citation_analysis attribute="neither">).</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0002"><label>Table 2</label><caption><p><citation_analysis attribute="neither">Clinical Characteristics of Lung Adenocarcinoma Patients</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Characteristics</th><th rowspan="1" colspan="1">AHI&lt;5 (n=7)</th><th rowspan="1" colspan="1">5≤AHI&lt;15 (n=6)</th><th rowspan="1" colspan="1">AHI≥15 (n=8)</th><th rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sex, female (%)</td><td rowspan="1" colspan="1">7 (100.00)</td><td align="center" rowspan="1" colspan="1">3 (50.00)</td><td rowspan="1" colspan="1">2(22.22)</td><td rowspan="1" colspan="1">0.011</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">52.57±9.76</td><td rowspan="1" colspan="1">57.83±14.36</td><td rowspan="1" colspan="1">66.13±9.88</td><td rowspan="1" colspan="1">0.090</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">23.48±2.70</td><td rowspan="1" colspan="1">23.64±3.90</td><td rowspan="1" colspan="1">26.04±4.77</td><td rowspan="1" colspan="1">0.389</td></tr><tr><td rowspan="1" colspan="1">AHI (events/h)</td><td rowspan="1" colspan="1">1.36±0.73</td><td rowspan="1" colspan="1">10.58±2.02</td><td rowspan="1" colspan="1">29.96±12.68</td><td rowspan="1" colspan="1">0.000</td></tr><tr><td rowspan="1" colspan="1">ODI (events/h)</td><td rowspan="1" colspan="1">5.83±2.05</td><td rowspan="1" colspan="1">12.20±4.14</td><td rowspan="1" colspan="1">23.41±10.42</td><td rowspan="1" colspan="1">0.000</td></tr><tr><td rowspan="1" colspan="1">CT90 (%)</td><td rowspan="1" colspan="1">0.73±1.28</td><td rowspan="1" colspan="1">7.63±10.04</td><td rowspan="1" colspan="1">18.31±30.72</td><td rowspan="1" colspan="1">0.146</td></tr><tr><td rowspan="1" colspan="1">LS<sub>P</sub>O<sub>2</sub>(%)</td><td rowspan="1" colspan="1">82.57±4.35</td><td rowspan="1" colspan="1">72.17±9.64</td><td rowspan="1" colspan="1">74.38±7.41</td><td rowspan="1" colspan="1">0.042</td></tr><tr><td rowspan="1" colspan="1">TNM stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.004</td></tr><tr><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">5(71.42)</td><td align="center" rowspan="1" colspan="1">1(16.67)</td><td rowspan="1" colspan="1">1(12.50)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">2(28.57)</td><td align="center" rowspan="1" colspan="1">2(33.33)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">III-IV</td><td rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3(50.00)</td><td rowspan="1" colspan="1">7(87.50)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Metastasis</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.032</td></tr><tr><td rowspan="1" colspan="1">NO</td><td rowspan="1" colspan="1">7 (100)</td><td align="center" rowspan="1" colspan="1">3(50.00)</td><td rowspan="1" colspan="1">3(37.50)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">YES</td><td rowspan="1" colspan="1">0 (0.00)</td><td align="center" rowspan="1" colspan="1">3(50.00)</td><td rowspan="1" colspan="1">5(62.50)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">MiR-142-3p level</td><td rowspan="1" colspan="1">0.85±0.66</td><td rowspan="1" colspan="1">0.57±0.22</td><td rowspan="1" colspan="1">0.21±0.28</td><td rowspan="1" colspan="1">0.033</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><citation_analysis attribute="positive"><bold>Abbreviations</bold></citation_analysis><citation_analysis attribute="neither">: BMI, body mass index; AHI, apnea–hypopnea index; ODI, oxygen desaturation index; CT90, percentage of time spent with oxygen saturation below 90%; LS</citation_analysis><citation_analysis attribute="positive"><sub>P</sub></citation_analysis><citation_analysis attribute="neither">O</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">, the lowest pulse oxygen saturation.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis></p>
        <p><citation_analysis attribute="neither">We examined the correlation between sleep parameters and pathological characteristics in Lung adenocarcinoma patients (</citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=385755.docx" ext-link-type="uri">Table S1</ext-link></underline></citation_analysis><citation_analysis attribute="neither">). The patients with advanced tumor stage had more severe OSA as messured by AHI and ODI (</citation_analysis><citation_analysis attribute="positive"><xref rid="f0001" ref-type="fig">Figure 1</xref></citation_analysis><citation_analysis attribute="positive">). However, no significant correlation was observed between LS</citation_analysis><citation_analysis attribute="positive"><sub>P</sub></citation_analysis><citation_analysis attribute="neither">O</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither"> and tumor stage.
</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0001" fig-type="figure"><label>Figure 1</label><caption><p><citation_analysis attribute="neither">Correlation between sleep parameters and pathological characteristics. (</citation_analysis><citation_analysis attribute="positive"><bold>A-B</bold></citation_analysis><citation_analysis attribute="neither">) Comparison of the OSA severity in the groups of lung adenocarcinoma patients and TNM stage. (</citation_analysis><citation_analysis attribute="positive"><bold>C-D</bold></citation_analysis><citation_analysis attribute="neither">) Comparison of the OSA severity in the groups of lung adenocarcinoma patients, with and without metastases.</citation_analysis></p></caption><graphic xlink:href="NSS-14-2047-g0001" content-type="print-only" position="float"/><attrib><bold>Abbreviations</bold>: AHI, apnea–hypopnea index; ODI, oxygen desaturation index.</attrib></fig></citation_analysis></p>
        <p><citation_analysis attribute="positive">Immunohistochemical analysis of HIF1α and ki67 expression was performed in Lung adenocarcinoma samples shown in </citation_analysis><citation_analysis attribute="positive"><xref rid="f0002" ref-type="fig">Figure 2</xref></citation_analysis><citation_analysis attribute="neither">. High expression of HIF1α and ki67 was observed in Lung adenocarcinoma patients with OSA. However, there is no dose relationship with OSA severity.
</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0002" fig-type="figure"><label>Figure 2</label><caption><p><citation_analysis attribute="neither">Immunohistochemistry pictures of HIF1α (</citation_analysis><citation_analysis attribute="positive"><bold>A</bold></citation_analysis><citation_analysis attribute="neither"> and </citation_analysis><citation_analysis attribute="positive"><bold>B</bold></citation_analysis><citation_analysis attribute="neither">) and ki67(</citation_analysis><citation_analysis attribute="positive"><bold>C</bold></citation_analysis><citation_analysis attribute="neither"> and </citation_analysis><citation_analysis attribute="positive"><bold>D</bold></citation_analysis><citation_analysis attribute="positive">) expression. Scale bars, 25um. Immunohistochemistry scores are shown (***P &lt; 0.001, ****P&lt; 0.0001, ns, P&gt;0.05).</citation_analysis></p></caption><graphic xlink:href="NSS-14-2047-g0002" content-type="print-only" position="float"/><attrib><bold>Abbreviations</bold>: IRS, immunoreactive score of Remmele and Stegner; AHI, apnea–hypopnea index.</attrib></fig></citation_analysis></p>
      </sec>
      <sec id="s0003-s2002">
        <title>The Level of miR-142-3p and Patient Characteristics</title>
        <p><citation_analysis attribute="neither">The qRT-PCR was performed to analyze the expression of miR-142-3p in 21 sets of Lung adenocarcinoma samples. Patients were divided into two groups according to the level of miR-142-3p (Median=0.530). No statistical differences were found in terms of gender, BMI, CT90, LS</citation_analysis><citation_analysis attribute="positive"><sub>P</sub></citation_analysis><citation_analysis attribute="neither">O</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither"> and metastasis rate between the two groups. While the patients with low miR-142-3p expression exhibited severe OSA, both AHI (7.35±6.36 VS 23.19±17.13, P= 0.018) and ODI (9.79±5.72 VS 19.36±11.82, P=0.027) were higher compared to another group. The patients with the low miR-142-3p expression group exhibited a higher TNM stage (P=0.012) (</citation_analysis><citation_analysis attribute="positive"><xref rid="t0003" ref-type="table">Table 3</xref></citation_analysis><citation_analysis attribute="neither">).</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0003"><label>Table 3</label><caption><p><citation_analysis attribute="neither">Comparison of the Baseline Characteristics Between Groups with High and Low Expression of miR-142-3p</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Characteristics</th><th rowspan="1" colspan="1">MiR-142-3p High</th><th rowspan="1" colspan="1">MiR-142-3p Low</th><th rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sex, female (%)</td><td rowspan="1" colspan="1">7(63.6%)</td><td rowspan="1" colspan="1">5(50%)</td><td rowspan="1" colspan="1">0.670</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">51.28±9.99</td><td rowspan="1" colspan="1">68.00±7.63</td><td rowspan="1" colspan="1">0.000</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">23.64±3.54</td><td rowspan="1" colspan="1">25.45±4.32</td><td rowspan="1" colspan="1">0.307</td></tr><tr><td rowspan="1" colspan="1">AHI (events/h)</td><td rowspan="1" colspan="1">7.35±6.36</td><td rowspan="1" colspan="1">23.19±17.13</td><td rowspan="1" colspan="1">0.018</td></tr><tr><td rowspan="1" colspan="1">ODI (events/h)</td><td rowspan="1" colspan="1">9.79±5.72</td><td rowspan="1" colspan="1">19.36±11.82</td><td rowspan="1" colspan="1">0.027</td></tr><tr><td rowspan="1" colspan="1">CT90 (%)</td><td rowspan="1" colspan="1">2.30±3.15</td><td rowspan="1" colspan="1">17.21±27.95</td><td rowspan="1" colspan="1">0.067</td></tr><tr><td rowspan="1" colspan="1">LS<sub>P</sub>O<sub>2</sub> (%)</td><td rowspan="1" colspan="1">78.73±6.34</td><td rowspan="1" colspan="1">74.00±9.70</td><td rowspan="1" colspan="1">0.198</td></tr><tr><td rowspan="1" colspan="1">TNM</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.012</td></tr><tr><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">6(54.55%)</td><td rowspan="1" colspan="1">1(10%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">3(27.27%)</td><td rowspan="1" colspan="1">1(10%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">III-IV</td><td rowspan="1" colspan="1">2(18.18%)</td><td rowspan="1" colspan="1">8(80%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Metastasis</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.080</td></tr><tr><td rowspan="1" colspan="1">NO</td><td rowspan="1" colspan="1">9(81.8%)</td><td rowspan="1" colspan="1">4(40%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">YES</td><td rowspan="1" colspan="1">2(18.2%)</td><td rowspan="1" colspan="1">6(60%)</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn0002"><p><citation_analysis attribute="positive"><bold>Abbreviations</bold></citation_analysis><citation_analysis attribute="neither">: BMI, body mass index; AHI, apnea–hypopnea index; ODI, oxygen desaturation index; CT90, percentage of time spent with oxygen saturation below 90%; LS</citation_analysis><citation_analysis attribute="positive"><sub>P</sub></citation_analysis><citation_analysis attribute="neither">O</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="neither">, the lowest pulse oxygen saturation.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis></p>
        <p><citation_analysis attribute="neither">We further analyzed the correlation of miR-142-3p expression with pathological characteristics and sleep parameters (</citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=385755.docx" ext-link-type="uri">Tables S2</ext-link></underline></citation_analysis><citation_analysis attribute="neither"> and </citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=385755.docx" ext-link-type="uri">S3</ext-link></underline></citation_analysis><citation_analysis attribute="neither">). We discovered that the miR-142-3p expression level was significantly lower in the advanced TNM stage (</citation_analysis><citation_analysis attribute="positive"><xref rid="f0003" ref-type="fig">Figure 3A</xref></citation_analysis><citation_analysis attribute="neither">), and there was a negatively correlated between miR-142-3p expression level with AHI (r= −0.505, p=0.020) and ODI (r= −0.513, p=0.017) (</citation_analysis><citation_analysis attribute="positive"><xref rid="f0003" ref-type="fig">Figure 3B–C</xref></citation_analysis><citation_analysis attribute="neither">).
</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0003" fig-type="figure"><label>Figure 3</label><caption><p><citation_analysis attribute="positive">Relationship of miR-142-3p levels with pathological characteristics and sleep parameters. A There was a significant difference in miR-142-3p levels between TNM stage subgroups; B-C The level of miR-142-3p was inversely correlated with AHI and ODI (r, the Pearson correlation coefficient).</citation_analysis></p></caption><graphic xlink:href="NSS-14-2047-g0003" content-type="print-only" position="float"/></fig></citation_analysis></p>
      </sec>
    </sec>
    <sec id="s0004">
      <title>Discussion</title>
      <p><citation_analysis attribute="neither">Several studies are in favor of a link between the increasing severity of OSA and lung cancer incidence and mortality.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0020" ref-type="bibr">20</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0021" ref-type="bibr">21</xref></citation_analysis><citation_analysis attribute="positive"> However, the association of the severity of OSA in specific Lung adenocarcinoma have not yet been fully elucidated. Firstly, lung adenocarcinoma patients were classified into three groups according to OSA severity as measured by AHI, and there was a significant difference in AHI, ODI, LS</citation_analysis><citation_analysis attribute="positive"><sub>P</sub></citation_analysis><citation_analysis attribute="neither">O</citation_analysis><citation_analysis attribute="positive"><sub>2</sub></citation_analysis><citation_analysis attribute="positive">, as well as TNM stage and Metastatic spreading. According to the analysis of the correlation between OSA values and lung cancer staging, AHI and ODI were significantly increased in advanced tumor stage, and as the severity of OSA worsens, it’s poor prognosis, suggesting the OSA severity contributes to the tumor malignant prognosis. Similar results were reported by the Wisconsin Sleep Cohort and Spanish cohort study; OSA severity as measured by AHI is correlated to elevated malignant tumor neoplasms incidence and malignant mortality in a dose-response relationship.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0022" ref-type="bibr">22</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="neither"> A prospective cohort study also found that in lung cancer patients with stage III and IV, severe OSA was an independent predictor of cancer mortality, and higher AHI had increased overall cancer mortality.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7</xref></citation_analysis><citation_analysis attribute="positive"> A cross-sectional study validated that OSA increased the risk of colorectal cancer onset, and abnormal ODI value was associated to a higher lymph node metastasis.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0024" ref-type="bibr">24</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Several potential mechanisms implicated a relationship between OSA and lung cancer incidence and mortality. In particular, OSA-related IH exacerbates lung cancer proliferation, stem cell-like properties, epithelial‑mesenchymal transition, and invasion.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0025" ref-type="bibr">25–28</xref></citation_analysis><citation_analysis attribute="neither"> It also has been elucidated the IH enhanced proliferative and migratory properties and invasiveness of tumors in a mouse model of sleep apnea.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0029" ref-type="bibr">29</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither"> In response to hypoxia, cancer cells set off downstream genes by activating the HIF family, particularly HIF1α, which plays a crucial role in accelerating cancer progression.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="positive"> Our findings confirmed that HIF1α was highly expressed in Lung adenocarcinoma patients with OSA but had no dose relationship with the AHI, which is inconsistent with reports that the expression of HIF1α was associated with the severity of OSA in lung cancer.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0020" ref-type="bibr">20</xref></citation_analysis><citation_analysis attribute="positive"> Due to the patients included in the cohort had more severe OSA (AHI &gt;30, n=11, 59.±20.8) comparing us (AHI &gt;30, n=4, 38.9±11.6). The more severe the hypoxia, the higher the expression of HIF1α. We first found that Ki67 was highly expressed in lung adenocarcinoma with OSA compared with lung adenocarcinoma. This suggested that IH promotes tumor proliferation.</citation_analysis></p>
      <p><citation_analysis attribute="positive">Emerging evidence suggests that hypoxia-repressed miR-142-3p targets HIF1α.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0015" ref-type="bibr">15</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither"> The function of miR-142-3p in inhibiting lung cancer progression, metastasis, invasion, and enhancing cell apoptosis has been validated.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0016" ref-type="bibr">16</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0017" ref-type="bibr">17</xref></citation_analysis><citation_analysis attribute="positive"> However, no studies about the role of miR-142-3p in lung cancer with OSA that investigated the suppressive effects on intermittent hypoxia. Our study first demonstrated the downregulation of miR-142-3p in Lung adenocarcinoma patients with OSA compared to patients without OSA, and the patients with low miR-142-3p expression exhibited severe OSA. Second, the expression of miR-142-3p significantly decreased in the advanced TNM stage. Additionally, miR-142-3p expression was negatively correlated with AHI and ODI. Previous studies also have found that low miR-142-3p expression level was significantly associated with advanced FIGO stage, lymph node metastasis, and depth of cervical invasion and was also related to the advanced stage metastatic melanoma.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0035" ref-type="bibr">35</xref></citation_analysis><citation_analysis attribute="neither"> Based on these previous studies and our data, we proposed that miR-142-3p could be used as an OSA severity indicator to predict the prognosis of lung cancer patients, suggesting that miR-142-3p may be a novel therapeutic hypoxia target.</citation_analysis></p>
      <p><citation_analysis attribute="negative">One of the limitations of this study is the short-term follow-up, and further long-term follow-up is needed to assess the cancer-related mortality to provide more conclusive evidence. Another limitation is that the sample size is too small, especially the sample of lung adenocarcinoma patients with moderate (15≤AHI&lt;30) and severe (AHI≥30) OSA, we will conduct further research to confirm our hypothesis.</citation_analysis></p>
    </sec>
    <sec id="s0005">
      <title>Conclusion</title>
      <p><citation_analysis attribute="positive">In this study, we demonstrated the correlation between OSA severity and malignant prognosis in lung adenocarcinoma patients. In addition, OSA may down-regulated the miR-142-3p expression in patients with Lung adenocarcinoma, and the expression of miR-142-3p was inversely correlated with AHI and ODI as a surrogate of OSA severity. Furthermore, low miR-142-3p expression level was significantly associated with the advanced TNM stage. The findings bring us to the attention that miR-142-3p may be an OSA severity indicator to predict the prognosis of lung cancer patients, implying that miR-142-3p is a potential hypoxia therapeutic target.</citation_analysis></p>
    </sec>
  </body>
  <back>
    <sec id="s0006">
      <title>Ethics Statement</title>
      <p><citation_analysis attribute="neither">The study has been submitted for approval by the Ethics Committee of The Second Affiliated Hospital of Kunming Medical University (PJ-2021-65). All participating patients in the study have signed informed consent.</citation_analysis></p>
    </sec>
    <sec sec-type="COI-statement" id="s0007">
      <title>Disclosure</title>
      <p><citation_analysis attribute="neither">The authors have no conflict of interest to declare for this work.</citation_analysis></p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="cit0001">
        <label>1.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hunyor</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Cook</surname>
<given-names>KM</given-names></string-name>. <article-title>Models of intermittent hypoxia and obstructive sleep apnea: molecular pathways and their contribution to cancer</article-title>. <source><italic toggle="yes">Am J Physiol Regul Integr Comp Physiol</italic></source>. <year>2018</year>;<volume>315</volume>(<issue>4</issue>):<fpage>R669</fpage>–<lpage>r87</lpage>. doi:<pub-id pub-id-type="doi">10.1152/ajpregu.00036.2018</pub-id><pub-id pub-id-type="pmid">29995459</pub-id></mixed-citation>
      </ref>
      <ref id="cit0002">
        <label>2.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Torres</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Sánchez-de-la-Torre</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Barbé</surname>
<given-names>F</given-names></string-name>. <article-title>Relationship between OSA and hypertension</article-title>. <source><italic toggle="yes">Chest</italic></source>. <year>2015</year>;<volume>148</volume>(<issue>3</issue>):<fpage>824</fpage>–<lpage>832</lpage>. doi:<pub-id pub-id-type="doi">10.1378/chest.15-0136</pub-id><pub-id pub-id-type="pmid">25879807</pub-id></mixed-citation>
      </ref>
      <ref id="cit0003">
        <label>3.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gonzaga</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Bertolami</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bertolami</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Amodeo</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Calhoun</surname>
<given-names>D</given-names></string-name>. <article-title>Obstructive sleep apnea, hypertension and cardiovascular diseases</article-title>. <source><italic toggle="yes">J Hum Hypertens</italic></source>. <year>2015</year>;<volume>29</volume>(<issue>12</issue>):<fpage>705</fpage>–<lpage>712</lpage>. doi:<pub-id pub-id-type="doi">10.1038/jhh.2015.15</pub-id><pub-id pub-id-type="pmid">25761667</pub-id></mixed-citation>
      </ref>
      <ref id="cit0004">
        <label>4.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lyons</surname>
<given-names>OD</given-names></string-name>, <string-name><surname>Ryan</surname>
<given-names>CM</given-names></string-name>. <article-title>Sleep apnea and stroke</article-title>. <source><italic toggle="yes">Can J Cardiol</italic></source>. <year>2015</year>;<volume>31</volume>(<issue>7</issue>):<fpage>918</fpage>–<lpage>927</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cjca.2015.03.014</pub-id><pub-id pub-id-type="pmid">26112302</pub-id></mixed-citation>
      </ref>
      <ref id="cit0005">
        <label>5.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kerner</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Roose</surname>
<given-names>SP</given-names></string-name>. <article-title>Obstructive sleep apnea is linked to depression and cognitive impairment: evidence and potential mechanisms</article-title>. <source><italic toggle="yes">Am J Geriatr Psychiatry</italic></source>. <year>2016</year>;<volume>24</volume>(<issue>6</issue>):<fpage>496</fpage>–<lpage>508</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jagp.2016.01.134</pub-id><pub-id pub-id-type="pmid">27139243</pub-id></mixed-citation>
      </ref>
      <ref id="cit0006">
        <label>6.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Justeau</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Gervès-Pinquié</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Le Vaillant</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Association between nocturnal hypoxemia and cancer incidence in patients investigated for OSA: data from a large multicenter French cohort</article-title>. <source><italic toggle="yes">Chest</italic></source>. <year>2020</year>;<volume>158</volume>(<issue>6</issue>):<fpage>2610</fpage>–<lpage>2620</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chest.2020.06.055</pub-id><pub-id pub-id-type="pmid">32629036</pub-id></mixed-citation>
      </ref>
      <ref id="cit0007">
        <label>7.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Huang</surname>
<given-names>HY</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>SW</given-names></string-name>, <string-name><surname>Chuang</surname>
<given-names>LP</given-names></string-name>, et al. <article-title>Severe OSA associated with higher risk of mortality in stage III and IV lung cancer</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2020</year>;<volume>16</volume>(<issue>7</issue>):<fpage>1091</fpage>–<lpage>1098</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.8432</pub-id><pub-id pub-id-type="pmid">32209219</pub-id></mixed-citation>
      </ref>
      <ref id="cit0008">
        <label>8.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>D</given-names></string-name>, et al. <article-title>Development and validation of a prognostic nomogram in lung cancer with obstructive sleep apnea syndrome</article-title>. <source><italic toggle="yes">Front Med</italic></source>. <year>2022</year>;<volume>9</volume>:<fpage>810907</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmed.2022.810907</pub-id></mixed-citation>
      </ref>
      <ref id="cit0009">
        <label>9.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Yap</surname>
<given-names>DWT</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>NKW</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>BKJ</given-names></string-name>, et al. <article-title>The Association of obstructive sleep apnea with breast cancer incidence and mortality: a systematic review and meta-analysis</article-title>. <source><italic toggle="yes">J Breast Cancer</italic></source>. <year>2022</year>;<volume>2022</volume>:<fpage>25</fpage>.</mixed-citation>
      </ref>
      <ref id="cit0010">
        <label>10.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Choi</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>KD</given-names></string-name>, <string-name><surname>Lim</surname>
<given-names>YC</given-names></string-name>, <string-name><surname>Cho</surname>
<given-names>JH</given-names></string-name>. <article-title>Association between obstructive sleep apnoea and breast cancer: the Korean national health insurance service data 2007–2014</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>19044</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-019-55551-7</pub-id><pub-id pub-id-type="pmid">31836779</pub-id></mixed-citation>
      </ref>
      <ref id="cit0011">
        <label>11.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Nieto</surname>
<given-names>FJ</given-names></string-name>, <string-name><surname>Peppard</surname>
<given-names>PE</given-names></string-name>, <string-name><surname>Young</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Finn</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Hla</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Farré</surname>
<given-names>R</given-names></string-name>. <article-title>Sleep-disordered breathing and cancer mortality: results from the Wisconsin sleep cohort study</article-title>. <source><italic toggle="yes">Am J Respir Crit Care Med</italic></source>. <year>2012</year>;<volume>186</volume>(<issue>2</issue>):<fpage>190</fpage>–<lpage>194</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.201201-0130OC</pub-id><pub-id pub-id-type="pmid">22610391</pub-id></mixed-citation>
      </ref>
      <ref id="cit0012">
        <label>12.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hao</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Gao</surname>
<given-names>J</given-names></string-name>. <article-title>Effect of chronic intermittent hypoxia-induced HIF-1α/ATAD2 expression on lung cancer stemness</article-title>. <source><italic toggle="yes">Cell Mol Biol Lett</italic></source>. <year>2022</year>;<volume>27</volume>(<issue>1</issue>):<fpage>44</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s11658-022-00345-5</pub-id><pub-id pub-id-type="pmid">35672694</pub-id></mixed-citation>
      </ref>
      <ref id="cit0013">
        <label>13.</label>
        <mixed-citation publication-type="journal"><string-name><surname>de Heer</surname>
<given-names>EC</given-names></string-name>, <string-name><surname>Jalving</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Harris</surname>
<given-names>AL</given-names></string-name>. <article-title>HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer</article-title>. <source><italic toggle="yes">J Clin Invest</italic></source>. <year>2020</year>;<volume>130</volume>(<issue>10</issue>):<fpage>5074</fpage>–<lpage>5087</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI137552</pub-id><pub-id pub-id-type="pmid">32870818</pub-id></mixed-citation>
      </ref>
      <ref id="cit0014">
        <label>14.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gao</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Zhan</surname>
<given-names>N</given-names></string-name>, et al. <article-title>Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma</article-title>. <source><italic toggle="yes">J Exp Clin Cancer Res</italic></source>. <year>2020</year>;<volume>39</volume>(<issue>1</issue>):<fpage>137</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13046-020-01641-8</pub-id><pub-id pub-id-type="pmid">32677981</pub-id></mixed-citation>
      </ref>
      <ref id="cit0015">
        <label>15.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Saatci</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Kaymak</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Raza</surname>
<given-names>U</given-names></string-name>, et al. <article-title>Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer</article-title>. <source><italic toggle="yes">Nat Commun</italic></source>. <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>2416</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-020-16199-4</pub-id><pub-id pub-id-type="pmid">32415208</pub-id></mixed-citation>
      </ref>
      <ref id="cit0016">
        <label>16.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jin</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Xiao</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Tian</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ren</surname>
<given-names>S</given-names></string-name>. <article-title>MiR-142-3p suppresses the proliferation, migration and invasion through inhibition of NR2F6 in lung adenocarcinoma</article-title>. <source><italic toggle="yes">Hum Cell</italic></source>. <year>2019</year>;<volume>32</volume>(<issue>4</issue>):<fpage>437</fpage>–<lpage>446</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13577-019-00258-0</pub-id><pub-id pub-id-type="pmid">31168689</pub-id></mixed-citation>
      </ref>
      <ref id="cit0017">
        <label>17.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Tian</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>W</given-names></string-name>, et al. <article-title>MicroRNA-142-3p/MALAT1 inhibits lung cancer progression through repressing β-catenin expression</article-title>. <source><italic toggle="yes">Biomed Pharmacother</italic></source>. <year>2019</year>;<volume>114</volume>:<fpage>108847</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biopha.2019.108847</pub-id><pub-id pub-id-type="pmid">30970294</pub-id></mixed-citation>
      </ref>
      <ref id="cit0018">
        <label>18.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Rami-Porta</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Asamura</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Travis</surname>
<given-names>WD</given-names></string-name>, <string-name><surname>Rusch</surname>
<given-names>VW</given-names></string-name>. <article-title>Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual</article-title>. <source><italic toggle="yes">CA Cancer J Clin</italic></source>. <year>2017</year>;<volume>67</volume>(<issue>2</issue>):<fpage>138</fpage>–<lpage>155</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21390</pub-id><pub-id pub-id-type="pmid">28140453</pub-id></mixed-citation>
      </ref>
      <ref id="cit0019">
        <label>19.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Sateia</surname>
<given-names>MJ</given-names></string-name>. <article-title>International classification of sleep disorders-third edition: highlights and modifications</article-title>. <source><italic toggle="yes">Chest</italic></source>. <year>2014</year>;<volume>146</volume>(<issue>5</issue>):<fpage>1387</fpage>–<lpage>1394</lpage>. doi:<pub-id pub-id-type="doi">10.1378/chest.14-0970</pub-id><pub-id pub-id-type="pmid">25367475</pub-id></mixed-citation>
      </ref>
      <ref id="cit0020">
        <label>20.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Huang</surname>
<given-names>HY</given-names></string-name>, <string-name><surname>Shih-Wei</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Chuang</surname>
<given-names>LP</given-names></string-name>, et al. <article-title>Severe obstructive sleep apnea associated with higher risk of mortality in stage III and IV lung cancer</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2020</year>;<volume>2020</volume>:<fpage>1</fpage>.</mixed-citation>
      </ref>
      <ref id="cit0021">
        <label>21.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Cheng</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Yao</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Yao</surname>
<given-names>Q</given-names></string-name>. <article-title>Obstructive sleep apnea and incidence of malignant tumors: a meta-analysis</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2021</year>;<volume>84</volume>:<fpage>195</fpage>–<lpage>204</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2021.05.029</pub-id><pub-id pub-id-type="pmid">34166986</pub-id></mixed-citation>
      </ref>
      <ref id="cit0022">
        <label>22.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Martínez-García</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Campos-Rodriguez</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Barbé</surname>
<given-names>F</given-names></string-name>. <article-title>Cancer and OSA: current evidence from human studies</article-title>. <source><italic toggle="yes">Chest</italic></source>. <year>2016</year>;<volume>150</volume>(<issue>2</issue>):<fpage>451</fpage>–<lpage>463</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chest.2016.04.029</pub-id><pub-id pub-id-type="pmid">27164292</pub-id></mixed-citation>
      </ref>
      <ref id="cit0023">
        <label>23.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Campos-Rodriguez</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Martinez-Garcia</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Martinez</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Association between obstructive sleep apnea and cancer incidence in a large multicenter Spanish cohort</article-title>. <source><italic toggle="yes">Am J Respir Crit Care Med</italic></source>. <year>2013</year>;<volume>187</volume>(<issue>1</issue>):<fpage>99</fpage>–<lpage>105</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.201209-1671OC</pub-id><pub-id pub-id-type="pmid">23155146</pub-id></mixed-citation>
      </ref>
      <ref id="cit0024">
        <label>24.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Xiong</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Lao</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>S</given-names></string-name>, et al. <article-title>A cross-sectional study of obstructive sleep apnea in patients with colorectal cancer</article-title>. <source><italic toggle="yes">J Gastrointest Oncol</italic></source>. <year>2022</year>;<volume>13</volume>(<issue>2</issue>):<fpage>683</fpage>–<lpage>694</lpage>. doi:<pub-id pub-id-type="doi">10.21037/jgo-22-175</pub-id><pub-id pub-id-type="pmid">35557570</pub-id></mixed-citation>
      </ref>
      <ref id="cit0025">
        <label>25.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>ESM1/HIF‑1α pathway modulates chronic intermittent hypoxia‑induced non‑small‑cell lung cancer proliferation, stemness and epithelial‑mesenchymal transition</article-title>. <source><italic toggle="yes">Oncol Rep</italic></source>. <year>2021</year>;<volume>45</volume>(<issue>3</issue>):<fpage>1226</fpage>–<lpage>1234</lpage>. doi:<pub-id pub-id-type="doi">10.3892/or.2020.7913</pub-id><pub-id pub-id-type="pmid">33650648</pub-id></mixed-citation>
      </ref>
      <ref id="cit0026">
        <label>26.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hao</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Z</given-names></string-name>, et al. <article-title>Chronic intermittent hypoxia promoted lung cancer stem cell-like properties via enhancing Bach1 expression</article-title>. <source><italic toggle="yes">Respir Res</italic></source>. <year>2021</year>;<volume>22</volume>(<issue>1</issue>):<fpage>58</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12931-021-01655-6</pub-id><pub-id pub-id-type="pmid">33596919</pub-id></mixed-citation>
      </ref>
      <ref id="cit0027">
        <label>27.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Chao</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Shang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ji</surname>
<given-names>W</given-names></string-name>. <article-title>ALKBH5-m(6)A-FOXM1 signaling axis promotes proliferation and invasion of lung adenocarcinoma cells under intermittent hypoxia</article-title>. <source><italic toggle="yes">Biochem Biophys Res Commun</italic></source>. <year>2020</year>;<volume>521</volume>(<issue>2</issue>):<fpage>499</fpage>–<lpage>506</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2019.10.145</pub-id><pub-id pub-id-type="pmid">31677788</pub-id></mixed-citation>
      </ref>
      <ref id="cit0028">
        <label>28.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Li</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Wen</surname>
<given-names>F</given-names></string-name>, et al. <article-title>Intermittent hypoxia-induced downregulation of microRNA-320b promotes lung cancer tumorigenesis by increasing CDT1 via USP37</article-title>. <source><italic toggle="yes">Mol Ther Nucleic Acids</italic></source>. <year>2021</year>;<volume>24</volume>:<fpage>528</fpage>–<lpage>541</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.omtn.2020.12.023</pub-id><pub-id pub-id-type="pmid">33898105</pub-id></mixed-citation>
      </ref>
      <ref id="cit0029">
        <label>29.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kang</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Kwon</surname>
<given-names>HY</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>IK</given-names></string-name>, et al. <article-title>Intermittent hypoxia exacerbates tumor progression in a mouse model of lung cancer</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1854</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-020-58906-7</pub-id><pub-id pub-id-type="pmid">32024881</pub-id></mixed-citation>
      </ref>
      <ref id="cit0030">
        <label>30.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Almendros</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Becker</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Intermittent hypoxia-induced changes in tumor-associated macrophages and tumor malignancy in a mouse model of sleep apnea</article-title>. <source><italic toggle="yes">Am J Respir Crit Care Med</italic></source>. <year>2014</year>;<volume>189</volume>(<issue>5</issue>):<fpage>593</fpage>–<lpage>601</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.201310-1830OC</pub-id><pub-id pub-id-type="pmid">24471484</pub-id></mixed-citation>
      </ref>
      <ref id="cit0031">
        <label>31.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hou</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>T</given-names></string-name>, et al. <article-title>DKC1 enhances angiogenesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancer</article-title>. <source><italic toggle="yes">Br J Cancer</italic></source>. <year>2020</year>;<volume>122</volume>(<issue>5</issue>):<fpage>668</fpage>–<lpage>679</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41416-019-0695-z</pub-id><pub-id pub-id-type="pmid">31857720</pub-id></mixed-citation>
      </ref>
      <ref id="cit0032">
        <label>32.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jögi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ehinger</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hartman</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Alkner</surname>
<given-names>S</given-names></string-name>. <article-title>Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2019</year>;<volume>14</volume>(<issue>12</issue>):<fpage>e0226150</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0226150</pub-id><pub-id pub-id-type="pmid">31821370</pub-id></mixed-citation>
      </ref>
      <ref id="cit0033">
        <label>33.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ou</surname>
<given-names>ZL</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ji</surname>
<given-names>LD</given-names></string-name>, et al. <article-title>Long noncoding RNA FEZF1-AS1 predicts poor prognosis and modulates pancreatic cancer cell proliferation and invasion through miR-142/HIF-1α and miR-133a/EGFR upon hypoxia/normoxia</article-title>. <source><italic toggle="yes">J Cell Physiol</italic></source>. <year>2019</year>;<volume>234</volume>:<fpage>15407</fpage>–<lpage>15419</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcp.28188</pub-id></mixed-citation>
      </ref>
      <ref id="cit0034">
        <label>34.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Li</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>BY</given-names></string-name>, <string-name><surname>Xia</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>LL</given-names></string-name>. <article-title>Expression of microRNA-142-3p in cervical cancer and its correlation with prognosis</article-title>. <source><italic toggle="yes">Eur Rev Med Pharmacol Sci</italic></source>. <year>2017</year>;<volume>21</volume>(<issue>10</issue>):<fpage>2346</fpage>–<lpage>2350</lpage>.<pub-id pub-id-type="pmid">28617557</pub-id></mixed-citation>
      </ref>
      <ref id="cit0035">
        <label>35.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tembe</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Schramm</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Stark</surname>
<given-names>MS</given-names></string-name>, et al. <article-title>MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis</article-title>. <source><italic toggle="yes">Pigment Cell Melanoma Res</italic></source>. <year>2015</year>;<volume>28</volume>(<issue>3</issue>):<fpage>254</fpage>–<lpage>266</lpage>. doi:<pub-id pub-id-type="doi">10.1111/pcmr.12343</pub-id><pub-id pub-id-type="pmid">25490969</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
